How to Avoid Expensive Redesign Cycles in Antibody Discovery

Summary

Most therapeutic antibody programmes do not fail at discovery. They stall afterwards, in rounds of redesign, when affinity, developability, specificity, or manufacturability were not addressed early enough. Each loop adds months, adds cost, and pushes a promising candidate further from the clinic. The expense is built in the moment a lead is selected for binding alone, and paid back later when the molecule meets the demands of development.

In this Scientist.com webinar, Maria Pajuelo, Co-founder and EVP of Technology and Scientific Office at FairJourney Bio, shows how integrating discovery and engineering moves a programme from initial hit to optimized lead in under 12 months. Drawing on real programme data, she covers early developability assessment, multiparametric optimization, and platform integration, and how each one removes downstream risk instead of deferring it. The session is sponsored by KACTUS. Watch it on demand to see where the redesign costs hide, and how to design them out from the first selection.